Prothena Co. plc (NASDAQ:PRTA - Get Free Report)'s share price traded down 9% on Friday . The stock traded as low as $12.84 and last traded at $12.88. 180,595 shares changed hands during mid-day trading, a decline of 57% from the average session volume of 420,744 shares. The stock had previously closed at $14.16.
Analysts Set New Price Targets
Several equities analysts recently commented on PRTA shares. HC Wainwright restated a "buy" rating and set a $48.00 target price (down from $84.00) on shares of Prothena in a research report on Friday, December 20th. Cantor Fitzgerald reissued an "overweight" rating on shares of Prothena in a report on Monday, September 30th. Chardan Capital initiated coverage on shares of Prothena in a report on Friday, December 20th. They issued a "buy" rating and a $40.00 price target on the stock. StockNews.com downgraded shares of Prothena from a "hold" rating to a "sell" rating in a report on Tuesday, November 19th. Finally, Bank of America reduced their target price on Prothena from $26.00 to $22.00 and set a "neutral" rating on the stock in a research note on Thursday, December 19th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, Prothena presently has a consensus rating of "Moderate Buy" and a consensus target price of $46.50.
Get Our Latest Report on PRTA
Prothena Price Performance
The stock has a 50 day moving average price of $14.99 and a 200-day moving average price of $18.47. The stock has a market capitalization of $702.21 million, a P/E ratio of -5.26 and a beta of 0.10.
Prothena (NASDAQ:PRTA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) EPS for the quarter, topping analysts' consensus estimates of ($1.18) by $0.08. The business had revenue of $0.97 million for the quarter, compared to analysts' expectations of $1.22 million. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%. The business's quarterly revenue was down 98.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.38 EPS. Research analysts predict that Prothena Co. plc will post -2.24 earnings per share for the current fiscal year.
Institutional Trading of Prothena
A number of institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its position in Prothena by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,344 shares of the biotechnology company's stock valued at $173,000 after purchasing an additional 4,026 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Prothena during the third quarter valued at approximately $210,000. XTX Topco Ltd purchased a new stake in Prothena in the third quarter worth $260,000. Orion Portfolio Solutions LLC boosted its holdings in Prothena by 4.4% in the third quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company's stock valued at $293,000 after acquiring an additional 739 shares in the last quarter. Finally, Creative Planning purchased a new position in Prothena during the 3rd quarter valued at $350,000. 97.08% of the stock is currently owned by hedge funds and other institutional investors.
Prothena Company Profile
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Further Reading
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
